Dabrafenib Plus Trametinib Demonstrates Benefit in BRAF-Mutant Melanoma
Axel Hauschild, MD, PhD, discusses the key findings from the phase 3 COMBI-AD clinical trial, which demonstrated sustained long-term relapse-free survival benefit with the combination of dabrafenib and trametinib compared with placebo in patients with resected, stage III BRAF V600E/K-mutated melanoma.
Axel Hauschild, MD, PhD, a professor of dermatology at the University Hospital Schleswig-Holstein, in Campus Kiel, Germany, discusses the key findings from the phase 3 COMBI-AD clinical trial, which demonstrated sustained long-term relapse-free survival benefit with the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) compared with placebo in patients with resected, stage III BRAF V600E/K-mutated melanoma.
In conclusion, we can say this is a highly effective treatment, says Hauschild. There is no doubt that for stage IIIA/B/C that this regimen will have benefit for patients.
One year of treatment with the combination of dabrafenib and trametinib is now considered the standard of care for this patient population, says Hauschild. This regimen is included in guidelines as the recommended treatment for patients with BRAF-mutant melanoma.
The overall survival data still need to be updated, but Hauschild says these findings are expected to be reported at some point within the next few years.
